CRIS stock icon

Curis
CRIS

$7.96
2.05%
 

About: Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 49

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

4.16% less ownership

Funds ownership: 39.62% [Q4 2023] → 35.46% (-4.16%) [Q1 2024]

11% less funds holding

Funds holding: 38 [Q4 2023] → 34 (-4) [Q1 2024]

24% less capital invested

Capital invested by funds: $29.8M [Q4 2023] → $22.7M (-$7.05M) [Q1 2024]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$26
227%
upside
Avg. target
$26
227%
upside
High target
$26
227%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
Robyn Karnauskas
227%upside
$26
Buy
Maintained
15 May 2024
HC Wainwright & Co.
Edward White
227%upside
$26
Buy
Reiterated
15 May 2024
HC Wainwright & Co.
Edward White
227%upside
$26
Buy
Reiterated
8 May 2024
HC Wainwright & Co.
Edward White
227%upside
$26
Buy
Maintained
9 Feb 2024

Financial journalist opinion